SPONSOR
Xijing Hospital
Total Trials
13
Recruiting
13
Phases
Phase 2
Conditions studied: Platelets-rich PlasmaOsteoarthritis Knees BothMeniscus DisorderCartilage InjuryAortic Valve Stenosis and InsufficiencyRenal CancerMetastasesPSMA PETHigh-risk Prostate CancerTreatment Response
Xijing Hospital is a clinical research sponsor with 13 registered studies on ClinicalTrials.gov, of which 13 are actively recruiting participants. Research covers conditions including Platelets-rich Plasma, Osteoarthritis Knees Both, Meniscus Disorder, Cartilage Injury.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Xijing Hospital
How many clinical trials has Xijing Hospital sponsored?
ClinicalMetric currently tracks 13 clinical trials sponsored by Xijing Hospital, of which 13 are actively recruiting participants. These trials cover conditions including Platelets-rich Plasma, Osteoarthritis Knees Both, Meniscus Disorder. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Xijing Hospital research focus on?
Xijing Hospital clinical trials span Platelets-rich Plasma, Osteoarthritis Knees Both, Meniscus Disorder, Cartilage Injury, Aortic Valve Stenosis and Insufficiency, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Xijing Hospital clinical trial?
To participate in a Xijing Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Xijing Hospital trials with current recruitment status updated daily.
Clinical Trials by Xijing Hospital
NCT06082531
Recruiting
Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis
Platelets-rich Plasma
NCT06379386
Recruiting
Long-term Prognosis and Valve Durability of TAVR
Aortic Valve Stenosis and Insufficiency
NCT04987086
Recruiting
68Ga-PSMA PET in the Renal Cell Carcinoma
Renal Cancer
NCT07553780
Recruiting
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
High-risk Prostate Cancer
NCT06558877
Recruiting
Effect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive Patients
Hypertension
NCT07750951 Phase 2
Recruiting
Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
NCT07586891
Recruiting
Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma
Melanoma (Skin Cancer)
NCT06257043
Recruiting
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
Aortic Valve Disease Mixed
NCT06308354
Recruiting
Colorectal Cancer Dataset in Xijing Hospital From 2011
Prognostic Cancer Model
NCT06938360
Recruiting
Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial
Breast Cancer
NCT07474142
Recruiting
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Newly Diagnosed, Treatment-naïve Prostate Cancer
NCT07492927
Recruiting
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Clinically Significant Prostate Cancer
NCT06830512
Recruiting
The Safety and Efficacy Evaluation of Echocardiography-guided Percutaneous Radiofrequency Ablation for Cardiac Tumors: a Single-arm, Prospective, Single-center Clinical Study
Heart Neoplasms
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology